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Rationale: Accumulating studies suggest that nitric oxide (NO) deficiency and oxidative
stress are central pathological mechanisms in type 2 diabetes (T2D). Recent findings
demonstrate therapeutic effects by boosting the nitrate-nitrite-NO pathway, which is an
alternative pathway for NO formation. This study aimed at investigating the acute effects
of inorganic nitrate on glucose and insulin signaling in adenosine A2B receptor knockout
mice (A
−/−
), a genetic mouse model of impaired metabolic regulation.2B
Methods: Acute effects of nitrate treatment were investigated in agedwild-type (WT) and
A
−/−
mice. One hour after injection with nitrate (0.1mmol/kg, i.p.) or placebo, metabolic2B
regulation was evaluated by intraperitoneal glucose and insulin tolerance tests. NADPH
oxidase-mediated superoxide production and AMPK phosphorylation were measured in
livers obtained from non-treated or glucose-treated mice, with or without prior nitrate
injection. Plasma was used to determine insulin resistance (HOMA-IR) and NO signaling.
Results: A
−/−
displayed increased body weight, reduced glucose clearance, and2B
attenuated overall insulin responses compared with age-matched WT mice. Nitrate
treatment increased circulating levels of nitrate, nitrite and cGMP in the A
−/−
, and2B
improved glucose clearance. In WT mice, however, nitrate treatment did not influence
glucose clearance. HOMA-IR increased following glucose injection in the A
−/−
, but2B
remained at basal levels in mice pretreated with nitrate. NADPH oxidase activity in
livers from A
−/−
, but not WT mice, was reduced by nitrate treatment. Livers from2B
A
−/−
displayed reduced AMPK phosphorylation compared with WT mice, and this was2B
increased by nitrate treatment. Finally, injection with the anti-diabetic agent metformin
induced similar therapeutic effects in the A
−/−
as observed with nitrate.2B
Conclusion: The A
−/−
mouse is a genetic mouse model of metabolic syndrome. Acute2B
treatment with nitrate improved the metabolic profile in it, at least partly via reduction in
oxidative stress and improved AMPK signaling in the liver.
Keywords: insulin resistance, metabolic syndrome, NADPH oxidase, nitric oxide, nitrite, superoxide, obesity, type
2 diabetes
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Introduction
Metabolic syndrome, which worsens during aging and obesity,
is a cluster of biochemical and physiological abnormalities that
increase the risk of developing cardiovascular disease and type
2 diabetes (T2D) (Eckel et al., 2005; Carlström, 2011). Reduced
nitric oxide (NO) production from endothelial nitric oxide
synthase (eNOS) and augmented oxidative stress are proposed
to be central events in metabolic syndrome (Litvinova et al.,
2015). In the past decade, an alternative pathway for NO
formation has been described where inorganic nitrate is serially
reduced to nitrite and then NO and other bioactive nitrogen
oxides (Lundberg et al., 2008, 2009, 2011). We have shown
that several features of metabolic syndrome present in aged
eNOS-deficient mice can be reversed by dietary supplementation
with inorganic nitrate (Carlström et al., 2010). A recent study
showed that chronic nitrite supplementation through increased
phosphorylation of the skeletal muscle AMP activated kinase
(AMPK) improved some metabolic syndrome components in a
model of obesity (Singamsetty et al., 2015). Moreover, chronic
treatment with nitrate attenuates oxidative stress and high
blood pressure in models of renal and cardiovascular disease
(Carlström et al., 2011a; Gao et al., 2015).
Adenosine is another important regulator of metabolism, and
signaling via its different receptor subtypes, A1, A2A, A2B, and
A3, has also gained a lot of interest (Chen et al., 2013). In a
recent publication we demonstrated that abrogation of adenosine
A1 signaling improves metabolic regulation in aged mice
by modulating nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activity and immune responses (Yang et al.,
2015a). Besides the A1 receptor, signaling via both A2A and
A2B receptors play important roles in modulating glucose
homeostasis and fat mass (Johnston-Cox et al., 2012; Gnad et al.,
2014). Another recent study suggested gene deletion of adenosine
A2B receptor as a suitable model for metabolic syndrome (Csóka
et al., 2014). The authors showed that A2B knockout mice
(A
−/−
2B ), fed a regular chow, displayed increased body weight
and fat mass, impaired glucose and insulin homeostasis, together
with dysregulated insulin, adipokine, triglyceride, and cholesterol
metabolism compared with wild-type (WT) control mice. Food
consumption was similar between genotypes, but daily walking
time was reduced in the A
−/−
2B mice. Moreover, Johnston-Cox
et al. reported that a high fat diet (HFD) aggravated the abnormal
metabolic phenotype in A
−/−
2B , whereas Csoka and colleagues did
not observe this.
The current study aimed at investigating the acute effects of
inorganic nitrate treatment on metabolic functions in aged A2B
receptor knockout mice (A
−/−
2B ). Considering previous findings
about nitrate- or nitrite-mediated modulation of both NADPH
oxidase (Montenegro et al., 2011; Carlström et al., 2011a; Gao
et al., 2015; Yang et al., 2015b) and AMPK (Kamga Pride
et al., 2014; Singamsetty et al., 2015), we hypothesized that
nitrate could improve abnormal metabolic functions during
aging and increased fat mass by increasing AMPK activation and
moderating oxidative stress. We observed improved metabolic
regulation in the A
−/−
2B mice after nitrate treatment and this
was indeed associated with decreased NADPH oxidase-derived
superoxide production in the liver, possibly mediated via restored
AMPK activation.
Materials and Methods
Animals
This study was approved by the Institutional Animal Care
and Use Committee (IACUC) in Stockholm, and performed
according to the National Institutes of Health guidelines for
the conduct of experiments in animals. Experiments were
conducted on aged (12–16 months) adenosine A2B receptor
gene-deleted and WT mice from heterozygous breeding pairs.
A
−/−
2B mice (a gift from professor M. Sitkovsky at Northwestern
University, Boston, Mass) were backcrossed 11 times to a
C57BL/6J background at Northwestern University. Both sexes
were used, with equal distribution for all experimental series.
Mice were housed in temperature-controlled rooms with 12 h
light/dark cycles and received a standard rodent chow (4% fat,
R34, Lactamin AB, Kimstad, Sweden) and tap water ad libitum.
An overview of the experimental protocol is shown in Figure 1.
Intraperitoneal Glucose, Insulin, and Pyruvate
Tolerance Tests
Glucose tolerance tests (IPGTT) were performed following 6 h
of fasting, as described previously (Yang et al., 2015a). Inorganic
nitrate (NaNO3; 0.1mmol/kg body weight) or placebo (NaCl,
0.1mmol/kg body weight) was administered intraperitoneally
60min prior to the tolerance tests. In a human (70 kg) this dose
of nitrate corresponds to around 450 mg; an amount found in a
single serving of a nitrate rich vegetable such as spinach, beetroot,
or lettuce (Weitzberg and Lundberg, 2013). A bolus of D-glucose
or pyruvate was injected (2 g/kg body weight; 30% in saline) and
tail blood was sampled at 0, 15, 30, 60, and 120min. Plasma
glucose was determined using a portable glucose meter (FreeStyle
Lite, Abbot Diabetes Care Inc, CA). In a cohort of A
−/−
2B mice
we also investigated the effects on glucose disposal with the anti-
diabetic drug metformin. Metformin (0.1mmol/kg body weight)
or placebo (NaCl, 0.1mmol/kg body weight) was administered
intraperitoneally 60min prior to the IPGTT. Homeostasis
model assessment-estimated insulin resistance (HOMA-IR) was
calculated at baseline, at 60min after injection with nitrate or
placebo, and again 30min after injection with glucose.
In order to investigate the acute effects of nitrate in a
model with more pronounced obesity, IPGTT were performed
as described above in WT mice given a HFD (34.9% fat,
D12492, Research Diets Inc., New Brunswick, NJ) for 14 months
(Supplementary Material).
Intraperitoneal insulin tolerance tests (IPITT) were
performed similarly to IPGTT without fasting. A bolus of
insulin (0.75 IE/kg body weight; Novorapid 100 IE/ml, Novo
Nordisk A/S, Denmark) was injected (0.2 IE/ml in saline) and
blood samples were obtained for plasma glucose measurements.
Plasma Analysis
Insulin content was measured using ELISAs purchased from
Mercodia (Uppsala, Sweden). Plasma samples containing IBMX
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FIGURE 1 | Experimental Protocol. Diagram of the experimental
procedures on aged WT or A2BKO mice undergoing intraperitoneal glucose
(IPGTT), pyruvate or insulin (IPITT) tolerance tests. In the termination series,
plasma and liver were collected at 0 or 30min. NaCl, sodium chloride;
NaNO3, sodium nitrate; IPGTT, intraperitoneal glucose tolerance test; IPITT,
intraperitoneal insulin tolerance test.
(10µM) were analyzed for cGMP using ELISA method (EIA
system; GE Healthcare). All kits were run according to
manufacturers’ instructions. Nitrite and nitrate were analyzed
by HPLC (ENO-20) and autosampler (840, EiCom, Kyoto,
Japan), as described previously (Carlström et al., 2010; Hezel
et al., 2015). The plasma samples were extracted using
methanol (1:2) and then centrifuged for 10min (4◦C; 10.000 g),
separated by reverse phase/ion exchange chromatography
followed by nitrate reduction to nitrite by cadmium and
reduced copper. The nitrite was then derivatized using Griess
reagent to form diazo compounds and analyzed by detection at
540 nm.
NADPH Oxidase Activity
NADPHoxidase-mediated superoxide formationwas detected by
lucigenin-dependent chemiluminescence assay (Carlstrom et al.,
2013; Yang et al., 2015a). Livers were separately homogenized and
used for subsequent activity measurement.
Western Blotting of AMPK
Livers obtained from mice under (1) basal condition, (2)
after pretreatment with placebo, nitrate or metformin,
and (3) after stimulation with glucose were weighed and
homogenized using 0.5mm zirconium oxide beads (Bullet
Blender™, Next Advance, Inc., Stockholm, Sweden) in 2.5
volumes of lysis buffer containing 10mM Tris-HCl (pH 8),
150mM NaCl, 5mM EDTA, 60mM N-octyl glucoside, 1%
Triton X-100, protease, and phosphatase inhibitor cocktails
(Sigma-Aldrich, Stockholm, Sweden). After centrifugation
and protein quantification of the soluble fraction (Protein
Assay Dye Reagent Concentrate; Bio-Rad Laboratories, Solna,
Sweden), equal amounts of protein were separated by SDS-PAGE
followed by transfer to a PVDF membrane (Bio-Rad). The
membranes were blocked with 5% nonfat dry milk in Tween-
containing TBS, incubated with specific primary antibody for
phosphorylated AMPK (Thr172; Cell signaling/BioNordika,
Stockholm, Sweden) and anti-rabbit secondary antibody
(horseradish peroxidase-conjugated goat antibody to rabbit
IgG, Santa Cruz, Heidelberg, Germany). To detect total
AMPK, Restore™ PLUS Western Blot Stripping Buffer
(Thermo Scientific™, Göteborg, Sweden) was applied followed
by blocking and re-probing the membranes with primary
antibody for AMPK (Cell Signaling/BioNordika) and anti-rabbit
secondary antibody. Protein bands were visualized using Clarity
Western ECL Substrate (Bio-Rad), intensities were quantified
using densitometry (Image Lab 5.2.1 software, Bio-Rad) and
results are reported as relative optical density of the specific
proteins.
Statistical Analysis
Values are presented as means ± SEM. Single comparisons
between normally distributed parameters were tested for
significance using the Student’s paired or unpaired t-test
as appropriate. For multiple group comparisons, One-Way
ANOVA followed by Bonferroni’s post-hoc test was used to allow
for more than one comparison with the same variable. Statistical
significance was defined as p < 0.05.
Frontiers in Physiology | www.frontiersin.org 3 August 2015 | Volume 6 | Article 222
Peleli et al. Inorganic nitrate improves metabolic function
Results
Animal Characteristics
Body weight was significantly higher in aged (12–16 months)
A
−/−
2B (36.5 ± 0.8 g; n = 42) compared with age-matched WT
mice (32.5 ± 0.9 g; n = 40), and plasma glucose levels in non-
fasting mice were also higher in the A
−/−
2B mice (9.5 ± 0.4 vs.
7.6 ± 0.2mmol/L). WT mice fed with HFD for 14 months were
more obese (body weight; 60.6 ± 3.3 g; n = 10) compared with
the aged-matched mice on a regular chow (P < 0.05).
Glucose Tolerance Tests
To investigate the ability of acute inorganic nitrate treatment
to modulate the metabolic phenotype in aged A
−/−
2B mice
we performed glucose tolerance tests in aged A
−/−
2B and WT
mice 1 h after nitrate injection (NaNO3; 0.1mmol/kg body
weight). Fasting blood glucose levels were similar in A
−/−
2B
and WT mice and nitrate treatment had no influence on
glucose clearance in WT mice (Figure 2A). Interestingly, the
impaired glucose tolerance in A
−/−
2B mice compared to WT was
significantly improved after acute nitrate treatment (Figure 2B).
Administration of the anti-diabetic drug metformin to the A
−/−
2B
mice resulted in an even more pronounced increase in glucose
tolerance (Figure 2C). Similar to that observed in A
−/−
2B mice,
acute treatment with nitrate also improved glucose disposal
(AUC 1493 ± 91 vs. 1779 ± 118; n = 10) in HFD-treated mice
(Supplementary Material).
Pyruvate Tolerance Test
We probed whether nitrate influences gluconeogenesis in A
−/−
2B
mice, which could contribute to the production and clearance
of glucose. To this end, the administration of the gluconeogenic
substrate precursor pyruvate showed that there was no difference
in glucose production in mice with nitrate pretreatment. Hence,
nitrate had no significant impact on the gluconeogenesis
pathway. However, upon glucose production (after 60min), the
clearance rates of glucose were again significantly faster in nitrate
treated A
−/−
2B mice compared to placebo group (Figure 2D;
120min), confirming a promotion in glucose clearance upon
acute treatment with inorganic nitrate.
Insulin Tolerance Tests and HOMA-IR
Insulin sensitivity after insulin injection (IPITT) was lower in
A
−/−
2B mice (Figure 3B) compared to WT (Figure 3A) resulting
A B
C D
FIGURE 2 | IPGTT and Pyruvate test. The effect of inorganic nitrate on
glucose tolerance was determined by measuring plasma glucose levels in
WT mice (A) and A2BKO mice (B) after placebo (NaCl) or nitrate injection
(NaNO3). Glucose levels after injection of metformin were determined in
A2BKO mice to investigate the effect of the anti-diabetic drug in mice
with metabolic syndrome (C). The impaired glucose tolerance in A2BKO
mice compared to WT could be significantly improved both with NaNO3
and with metformin. Finally, to assess any potential effect of nitrate on
gluconeogenesis, a pyruvate tolerance test was performed (D). The total
AUC (mmol/L/min) for the 0–120min period was calculated. Values are
mean ± SEM, n = 10–16/group. *p < 0.05 vs. A2BKO (NaCl);
#p < 0.05
vs. WT.
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A
B
C
FIGURE 3 | IPITT and HOMA-IR. Plasma glucose levels in response
to insulin injection were not influenced by nitrate treatment in WT
(A) and A2BKO mice (B). HOMA-IR, a measure of insulin resistance,
increased following glucose injection in A2BKO mice, which was
prevented by prior nitrate treatment (C). Values are mean ± SEM,
n = 10–16/group. #p < 0.05 vs. WT; *p < 0.05 among the indicated
groups.
in higher AUC. Glucose clearance did not differ between placebo
or nitrate treated animals of both genotypes. In addition, insulin
resistance (expressed as HOMA-IR) during fasting condition
was similar in both genotypes but increased following glucose
injection in the A
−/−
2B mice (Figure 3C). This could be prevented
by prior injection with nitrate.
Nitrate, Nitrite, and cGMP in Plasma
Nitrate treatment increased plasma nitrate levels in both WT
and A
−/−
2B mice as expected (Figure 4A) and this increase was
even higher in A
−/−
2B mice compared to WT after glucose
A B
C D
E F
FIGURE 4 | Nitrate, nitrite and cGMP in plasma. Treatment with nitrate
significantly increased plasma levels of nitrate in both genotypes before (A)
and after glucose injection (B). Plasma nitrite levels were significantly increased
only in nitrate treated A2BKO mice after glucose (C, D). In A2BKO mice, nitrate
supplementation caused a significant increase of plasma cGMP levels both
before (E) and after glucose injection (F). Values are mean ± SEM,
n = 6–14/group. *p < 0.05 among the indicated groups.
injection (Figure 4B). Plasma nitrite levels were not different
between groups during fasting (Figure 4C) but after glucose
injection, A
−/−
2B mice treated with nitrate showed significantly
higher nitrite levels compared to WT and also A
−/−
2B placebo
group (Figure 4D). The second messenger cGMP, a central
downstream NO signaling target, was not influenced by nitrate
or glucose in WT mice (Figures 4E,F). However, in A
−/−
2B
mice treatment with nitrate resulted in a significant increase
in plasma cGMP levels compared to the placebo group and
WT mice.
NADPH Oxidase Activity in the Liver
NADPH oxidase-derived superoxide production in liver
homogenates from A
−/−
2B mice was significantly higher
compared to WT mice (Figure 5A). Interestingly, nitrate
treatment as well as injection of metformin significantly reduced
superoxide production whereas nitrate had no effect on NADPH
oxidase activity in WT mice. The same beneficial effects of
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A B
FIGURE 5 | NADPH oxidase activity in the liver. NADPH
oxidase-derived superoxide formation was measured with
lucigenin-dependent chemiluminescence signal in liver homogenates
derived from A2BKO and WT mice before (A) and after glucose
injection (B). A significantly increased NADPH oxidase activity was
observed in A2BKO compared to WT, which could be diminished by
prior injection of nitrate or metformin. Values are mean ± SEM,
n = 6–14/group. *p < 0.05 among the indicated groups.
A B
FIGURE 6 | AMPK regulation in the liver. Western blot was used
to determine AMPK expression and phosphorylation in liver. Before
(A) and after glucose injection (B), A2BKO mice showed significantly
lower AMPK activation compared to WT. This could be improved by
prior injection of nitrate or metformin. Three representative samples
per group obtained from different gels are shown together with
densitometric quantification, presented as ratio p-AMPK/AMPK. Values
are mean ± SEM, n = 4/group. *p < 0.05 among the indicated
groups.
nitrate and metformin were observed after glucose injection
(Figure 5B).
AMPK Regulation in the Liver
Expression and phosphorylation levels of AMPK were assessed
in liver tissue derived from all animal groups. The ratio
of phosphorylated AMPK to total AMPK, as a measure
of AMPK activation, was significantly lower in A
−/−
2B mice
compared to WT (Figures 6A,B). This could be partially rescued
by treatment with nitrate or metformin. As was the case
with the NADPH oxidase activity, AMPK activation could
also be improved with nitrate or metformin after glucose
injection.
Discussion
Aged A
−/−
2B Mice Present Characteristics of the
Metabolic Syndrome
We confirmed previous studies (Johnston-Cox et al., 2012; Csóka
et al., 2014) showing that aged A
−/−
2B mice present several features
of the metabolic syndrome; they are more obese than WT mice,
display hyperglycemia and poor glucose clearance.
Impaired Liver AMPK Activation Could
Contribute to the Metabolic Dysregulation in
Aged A
−/−
2B Mice
The mechanisms leading to the development of this impaired
metabolic regulation in the A
−/−
2B mice are still being investigated
and there are many unanswered questions. Major contributing
factors are elevated hepatic inflammation and IRS-2 expression
(Johnston-Cox et al., 2012) and augmented classical macrophage
activation in the adipose tissue (Csóka et al., 2014). In this
study we focused mainly on the liver since it is an organ of
high importance in glucose metabolism and T2D development
(Bechmann et al., 2012) and has not been extensively investigated
in A
−/−
2B mice. AMPK is an important intracellular energy
sensor and one of the key players in maintaining liver glucose
homeostasis (Viana et al., 2006; Wang et al., 2012), which is
often downregulated under hyperglycemic conditions (Kraegen
et al., 2006). The ability to activate liver AMPK is a major
reason why the anti-diabetic drugs metformin and 5-amino-4-
imidazolecarboxamide riboside (AICAR) were developed and
used as treatments (Towler and Hardie, 2007). In our study
we show for the first time that aged A
−/−
2B mice present
lower phosphorylation levels of liver AMPK compared to
normoglycemic WT mice of similar age. In agreement with
that, the AMPK activator metformin elevated liver AMPK
phosphorylation levels together with a remarkable improvement
of glucose clearance. Thus, one may speculate that impaired
AMPK activation is one of the factors contributing to metabolic
dysfunction in this animal model.
Elevated Liver NADPH Oxidase Activity Could
Contribute to the Metabolic Dysregulated
Phenotype of the Aged A
−/−
2B Mice
Another key regulator of liver glucose uptake and metabolism
is the enzyme family of NADPH oxidases. It is well known that
elevated levels of NADPH oxidase-derived superoxide in the
liver diminish glucose uptake and contribute to the development
of hyperglycemia (Guichard et al., 2008). To our knowledge,
this is the first study showing that A
−/−
2B mice present higher
levels of liver NADPH oxidase activity compared to WT, both
before and after glucose treatment. Therefore, the investigation
of pharmacological interventions to target liver NADPH oxidases
may be of great interest for the improvement of the metabolic
phenotype when the A2B receptors are ablated.
AMPK and NADPH Oxidases are Closely Linked
Several studies have indicated that pharmacological activation
of AMPK can reduce NADPH oxidase activity and expression
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in various target organs and cells like liver (Adachi and
Brenner, 2008), cardiomyocytes (Balteau et al., 2014), podocytes
(Piwkowska et al., 2010), and human umbilical vein endothelial
cells (Ceolotto et al., 2007). One mechanism leading to
reduced production reactive oxygen species (ROS) might be via
upregulated mRNA expression of the antioxidant enzymes SOD2
and catalase, as it was seen in activated hepatic stellate cells
treated with AMPK activators AICAR or metformin (Adachi and
Brenner, 2008). Another mechanism of how activated AMPK can
inhibit NADPH oxidase activity was shown in activated human
neutrophils where AMPK activation with AICAR prevented
phosphorylation and membrane translocation of the cytosolic
NADPH oxidase subunit p47phox, which are both crucial to the
enzyme activation (Alba et al., 2004). However, it is still unknown
if this inhibition of NADPH oxidases and ROS production by
p-AMPK can lead to improved glucose clearance. Speaking in
favor of this concept, activation of AMPK by inorganic nitrate or
metformin in our study was clearly associated with both reduced
NADPH oxidase activity and improved glucose tolerance in
A
−/−
2B mice. Functional AMPK may therefore be important as an
early warning system for oxidative stress to trigger compensatory
antioxidant effects, which in turn improve glucose uptake. Future
studies are needed to investigate if inorganic nitrate exerts
its beneficial effect via upregulation of antioxidant enzymes,
prevention of p47phox phosphorylation and translocation or
another mechanism.
The Nitrate-Nitrite-NO Pathway is Upregulated in
the Aged A
−/−
2B Mice
We and other groups have previously shown that long-term
treatment with inorganic nitrate or nitrite improves glucose
clearance, insulin sensitivity, and reduces visceral fat levels
during aging and obesity (Carlström et al., 2010; Hezel et al.,
2015; Singamsetty et al., 2015). However, the underlying
mechanisms of how inorganic nitrate and nitrite mediate their
beneficial effects remain to be elucidated. In the current study
we investigated if acute treatment with inorganic nitrate can
exert similar effects as observed with long-term supplementation.
Interestingly, nitrate treatment significantly increased the plasma
levels of nitrite and cGMP only in A
−/−
2B mice, but not in the
WT, and the increase in plasma nitrate levels was higher in
A
−/−
2B mice compared with WT after glucose load. Since the
baseline levels of nitrate, nitrite and cGMP were similar between
WT and A
−/−
2B it seems that the nitrate-nitrite-NO pathway is
sensitized in the absence of A2B receptors. Activation of the A2
receptors has been linked with increased NOS activation, and
therefore it is likely that the NOS function is compromised in the
A2B knockouts. There are publications showing that A2 receptor
signaling is associated with higher NO production in the renal
microvasculature (Carlström et al., 2011b) and in the liver during
ischemia/reperfusion injury (Peralta et al., 1999). Moreover, A2
receptor activation, especially of the type 2B, leads to higher
NO production in coronary artery endothelial cells (Olanrewaju
and Mustafa, 2000) and enhances vasorelaxation in mouse aorta
(Ansari et al., 2007). Another mechanism potentiating the action
of nitrate in the A
−/−
2B mice but not in WT might be via the
higher superoxide levels. Several studies in redox biology suggest
that stimulating NO production or antioxidant systems are more
potent when there are higher levels of ROS and in particular
superoxide (Wink et al., 2001; Silva et al., 2012; Araujo and
Wilcox, 2014). Since activation of A2B receptors can facilitate
NO production and mice lacking these receptors already present
higher levels of liver superoxide one could speculate that this
oxidative stress leads to a more prominent and faster activation
of the alternative nitrate-nitrite-NO pathway.
The Nitrate-Nitrite-NO Pathway in T2D: Clinical
and Experimental Data
In recent bibliography there are several experimental in vivo and
in vitro studies showing favorable effects of inorganic nitrate
and nitrite in T2D (Bahadoran et al., 2015). The proposed
mechanisms involve compensation for disturbed eNOS-derived
NO generation (Carlström et al., 2010), improved antioxidant
capacity (Khalifi et al., 2015), and increased pancreatic islet blood
flow and insulin secretion (Nyström et al., 2012). Moreover,
nitrate/nitrite-mediated NO production may also improve
insulin resistance and glucose uptake by activation of glucose
transporter 4 (GLUT4) (Jiang et al., 2014; Ohtake et al., 2015).
Apart from the experimental reports some clinical studies have
been conducted. So far there is evidence that inorganic nitrate or
nitrite could have beneficial effects on overweight or slight obese
patients or in T2D despite no clear correlation between T2D and
plasma or urinary levels of nitrate and nitrite (Bahadoran et al.,
2015). Joris et al. showed that supplementation with beetroot
juice, which is high in inorganic nitrate, improved postpranial
endothelial function in slight overweight or obese men (Joris
and Mensink, 2013). In patients with T2D, a single dose of
inorganic nitrate was suggested to lower basal plasma glucose
and improve oral glucose insulin sensitivity index, however no
improvement in glucose tolerance was observed (Cermak et al.,
2015). In another small study in patients with T2D, Gilchrist and
colleagues did not observe improvement in endothelial function
or insulin sensitivity (Gilchrist et al., 2013), but their findings
suggested that dietary nitrate could improve cognitive function
in diabetic patients (Gilchrist et al., 2014). Taken together, despite
several studies reporting beneficial properties with inorganic
nitrate and nitrite, the data from small size clinical studies are still
contradictory and clearly show the need for a carefully conducted
large-scale, long-term follow up trial in patients.
In summary, the present study demonstrates an important
influence of acute inorganic nitrate treatment in modulating
metabolic functions. In aged A2B receptor knockout mice,
characterized by metabolic syndrome, inorganic nitrate
improved their glucose clearance and this was associated with
increased AMPK activation and reduced NADPH oxidase
activity in the liver. Similar favorable effects of acute nitrate
on glucose disposal was also observed in HFD-treated obese
WT mice. Intriguingly, the dose of nitrate was similar to
what is found in a single serving of a green leafy vegetable;
the predominant dietary source of nitrate. These findings
suggest that the beneficial effects of inorganic nitrate act not
only long-term but also acutely and future studies should be
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aimed at determining the therapeutic value of dietary nitrate
supplementation in patients with metabolic disease.
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